Investment
Features
FeesSafety
Academy
More
Pluang+

Compare United States Brent Oil Fund LP (BNO) vs Gilead Sciences, Inc. (GILD) Price & Performance

United States Brent Oil Fund LPTrade
Gilead Sciences, Inc.Trade

Price performance (Past 24H)

Key statistics

United States Brent Oil Fund LP vs Gilead Sciences, Inc. — how do they compare? United States Brent Oil Fund LP trades at $50.73, while Gilead Sciences, Inc. trades at $135.55 (market cap $168.35B). The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while United States Brent Oil Fund LP pays none, and United States Brent Oil Fund LP is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.

BNOGILD
Sector
Commodities - EnergyHealth
52-Week High
$60.13$155.80
52-Week Low
$27.20$110.56
Market Cap
$168.35B
Enterprise Value
$191.42B
Dividend Yield
2.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

United States Brent Oil Fund LP

BNO is trading at $50.505, up 0.79% with a bullish technical outlook supported by moving averages. The oil market faces significant supply disruptions from Middle East tensions, particularly the Strait of Hormuz closure, creating volatility. Recent OPEC demand forecast cuts contrast with supply constraints, creating a complex fundamental backdrop for oil-related securities.

The stock presents opportunity from ongoing supply constraints but faces headwinds from demand destruction and inventory builds. Key risks include geopolitical resolution and demand volatility. Technical momentum remains positive near-term, but fundamental uncertainties require careful monitoring of oil market developments.

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.

Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About United States Brent Oil Fund LP

BNO is a commodity ETF that tracks the daily price of Brent crude oil futures. It provides exposure to the international oil benchmark, which often trades at a premium to the U.S. WTI benchmark, and is primarily used for short-term trading due to roll costs.

Read more on BNO

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD